Article Sidebar

PDF
Date Published: 05/01/2022
Abstract Views: 257
Views PDF: 180
DOI: https://doi.org/10.51298/vmj.v508i1.1545
Issue
Vol. 508 No. 1 (2021)
Section
Các bài báo
How to Cite
Văn Chủ, N. ., & Thị Uyên, L. . (2022). ASSESSMENT OF TUMOR BUDDING IN INVASIVE DUCTAL BREAST CARCINOMA BY DIGITAL PATHOLOGY. Vietnam Medical Journal, 508(1). https://doi.org/10.51298/vmj.v508i1.1545

ASSESSMENT OF TUMOR BUDDING IN INVASIVE DUCTAL BREAST CARCINOMA BY DIGITAL PATHOLOGY

Nguyễn Văn Chủ1,, Lê Thị Uyên1
1 K Hospital

Main Article Content

Abstract

In invasive breast carcinoma, tumor budding, high-grade correlates with tumor size, lymphavascular invasion, lymph node metastasis, and reduced 5-year survival of breast cancer patients. Purpose: (1) Determination of the tumor budding rates in invasive ductal breast carcinoma. (2) Commenting on some relationships between tumor budding levels and pathological characteristics. Methods: Tumor samples of 232 patients with invasive ductal breast cancer were digitized the conventional slides to identify Bds according to ITBCC 2016 by computer virtual microscope software and evaluated the relationship with some pathological features. Results: The rate of high-grade Bd of the grade III was 35.1%, higher than high-grade Bd of the grade I and II of 20.3%. Similarly, in high-grade Bd, breast cancer with lymph node metastasis was 41.8%, twices higher than the group without metastasis (20.3%). The rate of high-grade Bd in the pT3 tumors was 63.6%, higher than the pT1 & pT2 (25.8%). In the tumors with lymphavascular invasion, high-grade Bd was 35.6%, which was 1.5 times higher than that in the group without lymphatic infiltration of 22.5% (p<0.05). Conclusion: There is a strong correlation between high-grade Bd and large tumor, axillary lymph node metastasis, high grade, and lymphavascular invasion.

Article Details

Keywords

Tumor budding, Histopathology, Breast cancer, Digital pathology

References

1. Lugli A, Kirsch R, Ajioka Y, et al. Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. Sep 2017;30(9):1299-1311.
2. Liang F, Cao W, Wang Y, Li L, Zhang G, Wang Z. The prognostic value of tumor budding in invasive breast cancer. Pathology, research and practice. May 2013;209(5):269-75.
3. Gujam FJ, McMillan DC, Mohammed ZM, Edwards J, Going JJ. The relationship between tumour budding, the tumour microenvironment and survival in patients with invasive ductal breast cancer. British journal of cancer. Sep 29 2015;113(7):1066-74. doi:10.1038/bjc.2015.287
4. Sun Y, Liang F, Cao W, et al. Prognostic value of poorly differentiated clusters in invasive breast cancer. World journal of surgical oncology. Oct 12 2014;12:310.
5. Salhia B, Trippel M, Pfaltz K, et al. High tumor budding stratifies breast cancer with metastatic properties. Breast cancer research and treatment. Apr 2015;150(2):363-71.
6. Masilamani DS, P DK. Evaluation of clinicopathologic significance of tumor budding in breast carcinoma. International Journal of Clinical and Diagnostic Pathology. 2019;2(1):171-173.
7. Sriwidyani NP, Manuaba IBTW, Alit-Artha IG, Mantik-Astawa IN. Tumor Budding in Breast Carcinoma: Relation to E-Cadherin, MMP-9 Expression, and Metastasis Risk. Tumor budding, E-cadherin, MMP-9, metastasis, breast carcinoma. 2016. 2016-10-22 2016;5(3):5.
8. Renuka IV, Madhavi K, Premalatha P, Krishnamacharyulu P, Vaishnavi R. Tumor budding in invasive carcinoma of breast of No Special Type (NST): Value as a prognostic factor. IP J Diagn Pathol Oncol 2019;4(2):15-129.
9. Agarwal R, Khurana N, Singh T, Agarwal PN. Tumor budding in infiltrating breast carcinoma: Correlation with known clinicopathological parameters and hormone receptor status. Indian journal of pathology & microbiology. Apr-Jun 2019;62(2):222-225.